What are the contraindications of Entrectinib/Luo Shengquan?

Entrectinib (Entrectinib) is a targeted drug mainly used to treat non-small cell lung cancer and other tumors with ALK, ROS1 or TRK gene rearrangements. Although entrectinib has significant efficacy against a variety of cancers, it also has some contraindications that patients must carefully evaluate before using this drug.

First, entrectinib is contraindicated in patients with known allergies to the components of the drug or its excipients. Entrectinib must be avoided if the patient has had an allergic reaction such as rash, shortness of breath, or swelling of the face or throat. In addition, severe allergic reactions or drug intolerances may lead to interruption of treatment and may even be life-threatening in severe cases.

Secondly, entrectinib is contraindicated in pregnant and lactating women. Due to the potential teratogenicity or adverse effects on the fetus, entrectinib should be avoided in pregnant women. Use of entrectinib by pregnant women may cause abnormal fetal development, so before treatment, doctors usually recommend pregnancy screening to ensure that the patient is not pregnant. Breastfeeding women should also avoid using entrectinib because the drug may pass through breast milk and affect the health of the baby.

In addition, entrectinib should be used with caution in patients with severe hepatic impairment. This drug is mainly metabolized by the liver, so in patients with impaired liver function, the metabolism of the drug may be affected, increasing the adverse reactions of the drug. For patients with abnormal liver function, it is necessary to strictly monitor liver function when using entrectinib, and adjust the drug dose or choose other treatment options if necessary.

Entrectinib is also contraindicated in some patients with a history of cardiovascular disease. Especially for patients with severe heart disease, such as heart failure, arrhythmia, etc., entrectinib may increase the risk of cardiovascular events. Therefore, use of this drug in these patients requires extreme caution and adequate cardiovascular evaluation.

Reference materials:https://www.roche.com/products/rozlytrek